Lambrinex

Atorvastatin, the active ingredient in Lambrinex, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers cholesterol and reduces cardiovascular risk in adults with hypercholesterolemia.\n\nGNH India supplies Lambrinex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin is indicated for disorders of lipid metabolism and for cardiovascular risk reduction.\n\nHypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol levels.\nHyperlipidemia: improves overall lipid profile including triglycerides and HDL.\nPrevention of cardiovascular events: lowers the incidence of myocardial infarction, stroke and related events in at‑risk patients.

Adverse reactions may vary in frequency and severity.\n\nCommon Side Effects:\n- Muscle aches or weakness\n- Headache\n- Nausea or abdominal discomfort\n- Diarrhea\n- Elevated liver enzymes\n- Rash or itching\n\nSerious or Rare Side Effects:\n- Myopathy or rhabdomyolysis\n- Severe liver injury\n- Acute renal failure\n- Anaphylactic reactions\n- Persistent elevation of creatine kinase\n- Unexplained bleeding or bruising

Patients should be evaluated for liver function and muscle health before and during therapy.\n\nBaseline liver tests: assess hepatic enzymes prior to initiation.\nMonitor muscle symptoms: report unexplained muscle pain or weakness.\nAvoid in active liver disease: contraindicated in patients with hepatic impairment.\nDrug interactions: review concomitant medications that affect statin metabolism.\nPregnancy and lactation: use only if benefits outweigh risks.\nStore at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Atorvastatin may interact with several drug classes, requiring clinical attention.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) – risk of severe myopathy.\n- Gemfibrozil – increased risk of rhabdomyolysis.\n- Cyclosporine – heightened statin exposure.\n\nModerate Interactions (Monitor Closely):\n- Anticoagulants (warfarin) – possible alteration of INR.\n- Antidiabetic agents – may affect glycemic control.\n- Niacin – additive lipid‑lowering effect, monitor liver function.